An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone following Ruxolitinib in Subjects with Myelofibrosis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
May 18, 2018
End Date
November 10, 2020
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
May 18, 2018
End Date
November 10, 2020